Copyright
©The Author(s) 2022.
World J Clin Cases. Nov 16, 2022; 10(32): 11775-11788
Published online Nov 16, 2022. doi: 10.12998/wjcc.v10.i32.11775
Published online Nov 16, 2022. doi: 10.12998/wjcc.v10.i32.11775
Table 3 Relationships between the European Organization for Research and Treatment of Cancer Quality of Life-Core 30-item and its related factors at three time periods (S1, S2, and S3)
Characteristic | Global health status | Physical functioning | Role functioning | Emotional functioning | Cognitive functioning | Social functioning | ||||||||||||
S1 | S2 | S3 | S1 | S2 | S3 | S1 | S2 | S3 | S1 | S2 | S3 | S1 | S2 | S3 | S1 | S2 | S3 | |
Age | -0.55 | -0.96 | -0.01 | -0.61 | -2.291 | -1.01 | -0.79 | -0.83 | -2.261 | -0.49 | 1.08 | -0.81 | -0.7 | -0.5 | -1.11 | -1.21 | -2.071 | -1.99 |
Sex | -0.67 | 0.14 | -1.11 | -0.03 | -0.18 | -0.07 | -1.33 | -0.01 | -1.43 | 0.31 | 0.33 | -0.15 | -0.44 | 0.6 | -0.07 | -0.56 | -0.24 | -0.69 |
ECOG | 1.21 | -0.84 | 0.33 | 2.782 | 0.56 | 2.071 | 3.873 | -1.02 | 1.49 | 1.29 | 0.05 | 0.01 | 1.92 | 1.79 | -0.69 | -0.47 | -1.56 | -1.04 |
HTN | -1.23 | -0.7 | -0.44 | -0.56 | -0.84 | -0.29 | -1.47 | -0.16 | -0.05 | -0.3 | 0.52 | -0.11 | 0.41 | -1.07 | -0.4 | -1.32 | -1.23 | -0.32 |
DM | -0.05 | -0.41 | -2.03 | -0.06 | -0.32 | -2.07 | -0.7 | 0.48 | -0.97 | -0.48 | 0.7 | -1.2 | 0.96 | 0.55 | -0.83 | -0.77 | -1.41 | -1.58 |
HBV | 0.24 | 0.24 | 1.03 | 1.39 | 0.96 | 0.76 | -0.12 | 0.4 | -0.03 | -0.07 | 1.13 | 0.08 | 0.19 | 1.55 | 0.5 | -2.711 | -0.54 | -0.07 |
HCV | 1.2 | 0.18 | -0.75 | 0.95 | 0.36 | 0.08 | -0.49 | 0.32 | 0.28 | 0.17 | 1.34 | 0.96 | -0.62 | -0.15 | 0.92 | -0.41 | 0.59 | -0.07 |
Primary or recurrent tumor | -0.98 | -0.39 | -1.04 | -2.03 | -0.54 | -0.82 | -1.78 | -0.73 | -1.32 | -0.79 | 0.94 | 0.24 | -0.15 | 1.48 | 0.74 | -1.52 | 0.58 | -0.39 |
Primary cancera | 1.36 | 1.43 | 1.36 | 0.48 | 0.46 | 0.48 | 0.43 | 0.6 | 0.43 | 0.63 | 0.36 | 0.63 | 1.12 | 0.59 | 1.12 | 1 | 0.93 | 1 |
Previous definitive surgery | -1.33 | -0.83 | -1.16 | -1.25 | -1.12 | -1.14 | -0.81 | -0.66 | -0.51 | -0.63 | 0.92 | 0.27 | -0.78 | -0.07 | -0.26 | -1.31 | 0.24 | -0.4 |
Previous systemic chemotherapy | -1.57 | -1.86 | -2.151 | -0.99 | -0.9 | -1.1 | -1.37 | -1.05 | -1.52 | -0.89 | 0.43 | -0.93 | 0.29 | 0.45 | -1 | -1.37 | -0.71 | -1.99 |
PCIb | -0.05 | -0.02 | 0.1 | -0.15 | -0.12 | -0.13 | -0.15 | -0.12 | -0.05 | -0.22 | -0.04 | 0.04 | -0.11 | 0.03 | -0.01 | -0.01 | -0.05 | -0.05 |
CCa | 0.93 | 1.14 | 0.48 | 1.03 | 1.07 | 0.37 | 0.53 | 1.07 | 0.29 | 1.45 | 0.06 | 0.35 | 0.38 | 0.53 | 0.3 | 0.72 | 0.85 | 0.13 |
Duration of peritonectomy (min)b | -0.06 | -0.18 | 0.11 | 0.18 | -0.21 | 0.05 | 0.09 | -0.37 | -0.01 | 0.01 | 0.04 | 0.09 | -0.14 | 0.04 | -0.03 | -0.09 | -0.04 | 0.05 |
LOS (days)b | -0.13 | 0.14 | -0.03 | -0.02 | 0.1 | -0.07 | 0 | 0.06 | -0.12 | -0.01 | 0.2 | 0.03 | -0.26 | 0.13 | -0.05 | 0.09 | 0.18 | 0.07 |
Surgical method | 0.64 | -0.01 | 0.47 | 0.54 | 0.3 | 0.65 | 1.18 | 0.72 | 0.11 | 2.111 | 1.6 | 1.14 | 0.65 | 2.872 | 1.4 | 2.872 | 0.72 | -0.22 |
HIPEC regimen | -1.11 | -0.63 | -0.52 | -0.39 | 0.89 | 2.561 | -0.15 | 0.07 | -0.12 | -0.04 | -0.35 | 0.63 | -0.66 | 0.44 | 1.93 | -0.54 | -1.38 | 0.39 |
HIPEC indicationa | 0.95 | 0.15 | 1.16 | 1.34 | 0.44 | 0 | 0.39 | 0.47 | 0.01 | 0.93 | 0.11 | 0.15 | 0.02 | 0.22 | 0.08 | 1.54 | 1.39 | 0.15 |
Duration of HIPEC (mins) | 0.82 | 0.44 | 0.37 | 1.01 | -0.7 | -2.131 | 0.6 | 0.48 | 0.42 | 0.62 | 1.28 | -0.04 | 0.01 | -1.46 | -2.431 | 0.84 | 1.38 | -0.1 |
Post-op complicationsa | 0.62 | 0.54 | 2.05 | 0.69 | 0.88 | 0.19 | 0.51 | 0.99 | 0.67 | 0.4 | 0.34 | 1.34 | 2.24 | 1.51 | 1.25 | 0.48 | 1.15 | 2.61 |
PGSGA | 1.84 | 0.49 | 1.08 | 0.79 | 0.14 | 1.28 | -1.27 | -0.78 | 0.9 | 1.16 | -0.19 | -0.44 | 1.25 | 0.42 | 1.2 | -0.55 | 0.74 | 0.6 |
MDASI-T | ||||||||||||||||||
SSb | -0.483 | -0.34 | -0.7 | -0.38 | -0.46 | -0.52 | -0.3 | -0.453 | -0.483 | -0.342 | -0.493 | -0.643 | -0.543 | -0.2 | -0.723 | -0.24 | -0.331 | -0.613 |
DILb | -0.543 | -0.493 | -0.693 | -0.433 | -0.633 | -0.66 | -0.473 | -0.603 | -0.693 | -0.433 | -0.433 | -0.723 | -0.392 | -0.281 | -0.673 | -0.533 | -0.523 | -0.783 |
- Citation: Wang YF, Wang TY, Liao TT, Lin MH, Huang TH, Hsieh MC, Chen VCH, Lee LW, Huang WS, Chen CY. Quality of life and symptom distress after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Clin Cases 2022; 10(32): 11775-11788
- URL: https://www.wjgnet.com/2307-8960/full/v10/i32/11775.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i32.11775